Dr. Özge Gürsoy Yüzügüllü is a distinguished leader in the life sciences sector with over 15 years of experience in oncology and rare diseases. She has held pivotal roles at Carmine Therapeutics, Codiak BioSciences and Constellation Pharmaceuticals delivering exceptional results in team leadership, program management, and translational research with different modalities and drug delivery approaches. Notable for her role in executing and prioritizing IND-enabling experiments and contributing to strategic portfolio decisions, she has a proven track record of building and managing talented scientific teams. Her experience includes leading collaborations worth $6M+, developing drug discovery projects focusing on epigenetics and cancer signaling pathways, and pioneering cell-based assays for combinatorial cancer therapies. An alumna of Bilkent University with a Ph.D. in Molecular Biology and Genetics, Dr. Gürsoy Yüzügüllü has further enriched her expertise at Harvard Medical School as an Instructor. Her research in Dana Farber Cancer Institute advanced mechanism of epigenetic regulation and DNA damage response field. She has been published in high-impact journals, contributing valuable insights into epigenetics and DNA damage response. In January 2025, Dr. Gürsoy Yüzügüllü joined the HMS Therapeutics Initiative as a Scientific Project Manager, where she applies her extensive experience in academia and industry to forge alliances and advance therapeutic discovery.